The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review.
The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review.
复制标题
DOI：
10.1007/s40273-018-0631-8
复制
发表时间：
2018-07
影响因子：
4.4
通讯作者：
Maher TM
中科院分区：
文献类型：
--
作者：
Diamantopoulos A;Wright E;Vlahopoulou K;Cornic L;Schoof N;Maher TM
特发性肺纤维化（IPF）是一种使人衰弱的疾病，发病率高且生存率低。自 2010 年以来，旨在延缓疾病进展的治疗方法的开发活动不断增加。我们的研究涉及对健康相关生活质量 (HRQoL)、医疗资源使用 (HCRU) 和成本的文献进行全面回顾，并对疾病负担进行评估。我们进行了系统文献综述 (SLR)，以确定经济评估和 HRQoL 研究。我们检索了 EMBASE、MEDLINE 和 MEDLINE In Process，以查找从数据库起源到 2017 年 4 月的相关研究。除了介绍研究特征和现有证据外，我们还使用 HRQoL 的参考人群估计值和国家卫生支出成本进行了定性比较。我们的搜索总共找到了 3241 条记录。在删除重复和不相关的文章后，我们分析了 124 篇出版物，涉及 2000 年至 2017 年间发表的 88 项研究。60 项研究是 HRQoL，28 项是关于成本或 HCRU 的研究。我们观察到过去 3-5 年出版物呈指数增长，其中大部分研究在欧洲和北美进行。在HRQoL研究中，尽管存在地区差异，但与普通人群相比，IPF患者HRQoL的绝对和相对水平的估计之间存在一定的一致性。在费用方面，经过费用年份和货币的调整后，北美IPF患者的人均年费用估计约为2万美元，是国家医疗支出的2.5-3.5倍。此外，对 IPF 患者与匹配的对照队列进行分析的研究表明，资源使用和成本显着增加。审查的证据表明，相对于一般人群水平，IPF 对 HRQoL 有相当大的影响。此外，在成本和资源使用的研究中，大多数对负担的估计都一致表明，与对照组或国家卫生支出相比，IPF 患者的成本过高。这证实了 IPF 对全球公共卫生的威胁日益严重，对患者和医疗保健提供者产生了相当大的影响。本文的在线版本 (10.1007/s40273-018-0631-8) 包含补充材料，可供授权用户使用。
Idiopathic pulmonary fibrosis (IPF) is a debilitating condition with significant morbidity and poor survival. Since 2010, there has been increased activity in the development of treatments that aim to delay progression of the disease. Our study involves a comprehensive review of the literature for evidence on health-related quality of life (HRQoL), healthcare resource use (HCRU) and costs, and an assessment of the burden of illness of the condition. We carried out a systematic literature review (SLR) to identify economic evaluations and HRQoL studies. We searched EMBASE, MEDLINE and MEDLINE In Process for relevant studies from database origins to April 2017. Alongside the presentation of the study characteristics and the available evidence, we carried out a qualitative comparison using reference population estimates for HRQoL and national health expenditure for costs. Our search identified a total of 3241 records. After removing duplicates and not relevant articles, we analysed 124 publications referring to 88 studies published between 2000 and 2017. Sixty studies were HRQoL and 28 were studies on costs or HCRU. We observed an exponential growth of publications in the last 3–5 years, with the majority of the studies conducted in Europe and North America. Among the HRQoL studies, and despite regional differences, there was some agreement between estimates on the absolute and relative level of HRQoL for patients with IPF compared with the general population. Regarding costs, after adjustments for the cost years and currency, the suggested annual per capita cost of patients with IPF in North America was estimated around US$20,000, 2.5–3.5 times higher than the national healthcare expenditure. Additionally, studies that analysed patients with IPF alongside a matched control cohort suggested a significant increase in resource use and cost. The reviewed evidence indicates that IPF has considerable impact on HRQoL, relative to the general population levels. Furthermore, in studies of cost and resource use, most estimates of the burden were consistent in suggesting an excess cost for patients with IPF compared with a control cohort or the national health expenditure. This confirms IPF as a growing threat for public health worldwide, with considerable impact to the patients and healthcare providers. The online version of this article (10.1007/s40273-018-0631-8) contains supplementary material, which is available to authorized users.
登录
查看更多内容
影响因子：
8.3
作者：
Collard, Harold R.;Chen, Shih-Yin;Raghu, Ganesh
通讯作者：
Raghu, Ganesh
影响因子：
4.5
作者：
Ara, Roberta;Brazier, John E.
通讯作者：
Brazier, John E.
影响因子：
3.6
作者：
通讯作者：
--
影响因子：
4.1
作者：
Bors, Melinda;Tomic, Rade;Whelan, Timothy P. M.
通讯作者：
Whelan, Timothy P. M.
特发性肺纤维化进展的负担：一项 5 年纵向随访研究。
影响因子：
3.7
作者：
Cottin V;Schmidt A;Catella L;Porte F;Fernandez-Montoya C;Le Lay K;Bénard S
通讯作者：
Bénard S